Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5866_Библиотеки_им_академика_М_И_Перельмана
.pdf
replicas that, so far, cannot represent the complexity of the actual tissues. Nevertheless,
MNRs have demonstrated a great potential to deliver drugs to HeLa tumor cells. Until
now, due to ethical concerns, the few in vivo tests were carried out only in animal models
[180,181]. Two main issues come up from this approach: the first relates to the transfer-
ability of the results to humans that is often not confirmed; the second point concerns the
effective need of animal subjects which, throughout the research process, may suffer from
the outcomes of the experiments. Therefore, the search for more reliable in vitro platforms
to perform further studies on MNRs will be the next step for a deeper investigation in this
field. Such desired platforms encompass biological models, such as cancer tissue organoids
in which to test efficacy [182], as well as organ/organism models in which to test spatial
control during motion, such as phantoms [183].
References
[1] Alderton GK, Bordon Y. Tumour immunotherapy—leukocytes take up the fight. Nat Rev Immunol
2012;12:237.
[2] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer
2012;12:252–64.
[3] Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases.
Cell Mol Immunol 2013;10:230–52.
[4] Liu Y, Chen X-G, Yang P-P, Qiao Z-Y, Wang H. Tumor microenvironmental pH and enzyme dual
responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy. Biomacromolecules 2019;20:882–92.
[5] Chew SA, Danti S. Biomaterial-based implantable devices for cancer therapy. Adv Healthc Mater
2017;6:1600766.
[6] Lan X, Zhu W, Huang X, Yu Y, Xiao H, Jin L, et al. Microneedles loaded with anti-PD-1 – cisplatin
nanoparticles for synergistic cancer immuno-chemotherapy. Nanoscale 2020;12:18885–98.
[7] Gao S, Li T, Guo Y, Sun C, Xianyu B, Xu H. Selenium-containing nanoparticles combine the NK
cells mediated immunotherapy with radiotherapy and chemotherapy. Adv Mater 2020;32:1907568.
[8] Yong S-B, Kim J, Chung JY, Ra S, Kim SS, Kim Y-H. Heme oxygenase 1-targeted hybrid nano-
particle for chemo-and immuno-combination therapy in acute myelogenous leukemia. Adv Sci
2020;7:2000487.
[9] Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A. Enhancement of antitumor
activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin
2. Clin Cancer Res 1999;5:687–93.
[10] Navashenaq JG, Zamani P, Nikpoor AR, Tavakkol-Afshari J, Jaafari MR. Doxil chemotherapy plus
liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast
cancer. Nanomed Nanotechnol Biol Med 2020;24, 102150.
[11] Lu J, Liu X, Liao Y-P, Wang X, Ahmed A, Jiang W, et al. Breast cancer chemo-immunotherapy
through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1
pathway. ACS Nano 2018;12:11041–61.
[12] Tao Y, Ju E, Liu Z, Dong K, Ren J, Qu X. Engineered, self-assembled near-infrared photothermal
agents for combined tumor immunotherapy and chemo-photothermal therapy. Biomaterials
2014;35:6646–56.
[13] Xu J, Xu B, Tao J, Yang Y, Hu Y, Huang Y. Microneedle-assisted, DC-targeted Codelivery of
pTRP-2 and adjuvant of paclitaxel for transcutaneous immunotherapy. Small 2017;13:1700666.
[14] Shahbazi M-A, Shrestha N, M€akil€a E, Arau´jo F, Correia A, Ramos T, et al. A prospective cancer
chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon
nanovectors. Nano Res 2015;8:1505–21.
[15] Liang J, Wang H, Ding W, Huang J, Zhou X, Wang H, et al. Nanoparticle-enhanced chemo-
immunotherapy to trigger robust antitumor immunity. Sci Adv 2020;6, eabc3646.
125Biomaterials and devices for immunotherapy
126 Emily M. Jordan et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[16] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res
2020;10:727.
[17] Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor
antigen – specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally
impaired. Blood 2009;114:1537–44.
[18] Jin H-T, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. In: Negative
co-receptors ligands. Springer; 2010. p. 17–37.
[19] McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med
2013;2:662–73.
[20] Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer
and antibacterial drugs. Chem Biol 2010;17:421–33.
[21] Wang W, Kryczek I, Dosta´l L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated
chemoresistance in ovarian cancer. Cell 2016;165:1092–105.
[22] Park J-H, Jang M, Tarhan YE, Katagiri T, Sasa M, Miyoshi Y, et al. Clonal expansion of antitumor
T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol
2016;49:471–8.
[23] Enqvist M, Nilsonne G, Hammarfjord O, Wallin RPA, Bj€orkstr€om NK, Bj€ornstedt M, et al. Selenite
induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/
NKG2A-positive NK cells. J Immunol 2011;187:3546–54.
[24] Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D’Arcy P, Zhivotovsky B, et al. Doxorubicin
sensitizes human tumor cells to NK cell-and T-cell-mediated killing by augmented TRAIL receptor
signaling. Int J Cancer 2013;133:1643–52.
[25] Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh
syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer
Res 1984;44:1946–53.
[26] Ettinghausen SE, Lipford EH, Mule JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in vivo
proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. J Immunol
1985;135:3623–35.
[27] Cheever MA, Greenberg PD, Irle C, Thompson JA, Urdal DL, Mochizuki DY, et al. Interleukin 2
administered in vivo induces the growth of cultured T cells in vivo. J Immunol 1984;132:2259–65.
[28] Cheever MA, Greenberg PD, Fefer A. Potential for specific cancer therapy with immune
T lymphocytes. J Immunother 1984;3:113–27.
[29] Ettinghausen SE, Lipford EH, Mule JJ, Rosenberg SA. Systemic administration of recombinant inter-
leukin 2 stimulates in vivo lymphoid cell proliferation in tissues. J Immunol 1985;135:1488–97.
[30] Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treat-
ment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus
interleukin 2. JAMA 1994;271:907–13.
[31] Negrier S, Mercatello A, Bret M, Thiesse P, Blay JY, Coronel B, et al. Intravenous interleukin-2 in
patients over 65 with metastatic renal carcinoma. Br J Cancer 1992;65:723–6.
[32] Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on
the systemic administration of autologous lymphokine-activated killer cells and recombinant
interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485–92.
[33] Den Otter W, Jacobs JJL, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, et al. Local therapy of
cancer with free IL-2. Cancer Immunol Immunother 2008;57:931–
[34] Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-
epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomed Nanotechnol
Biol Med 2012;8:692–701.
[35] Gholizadeh Z, Tavakkol-Afshari J, Nikpoor AR, Jalali SA, Jaafari MR. Enhanced immune response
induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.
J Cell Mol Med 2018;22:558–67.
[36] Amir Jalali S, Parmiani G. Pre-clinical and clinical aspects of peptide-based vaccine against human
solid tumors. Recent Pat Biotechnol 2011;5:108–17.
[37] Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infec-
tious disease. Nat Rev Immunol 2017;17:97.
50.
[38] Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev
Immunol 2013;31:51–72.
[39] Rapoport BL, Anderson R. Realizing the clinical potential of immunogenic cell death in cancer che-
motherapy and radiotherapy. Int J Mol Sci 2019;20:959.
[40] Au KM, Balhorn R, Balhorn MC, Park SI, Wang AZ. High-performance concurrent chemo-
immuno-radiotherapy for the treatment of hematologic cancer through selective high-affinity ligand
antibody mimic-functionalized doxorubicin-encapsulated nanoparticles. ACS Cent Sci
2018;5:122–44.
[41] Zheng D-W, Chen J-L, Zhu J-Y, Rong L, Li B, Lei Q, et al. Highly integrated nano-platform for
breaking the barrier between chemotherapy and immunotherapy. Nano Lett 2016;16:4341–7.
[42] Mastria EM, Cai LY, Kan MJ, Li X, Schaal JL, Fiering S, et al. Nanoparticle formulation improves
doxorubicin efficacy by enhancing host antitumor immunity. J Control Release 2018;269:364–73.
[43] Pinzon-Charry A, Maxwell T, Lo´pez JA. Dendritic cell dysfunction in cancer: a mechanism for
immunosuppression. Immunol Cell Biol 2005;83:451– 61.
[44] Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the
tumour microenvironment. Nat Rev Immunol 2007;7:41–51.
[45] Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov
2006;5:471–84.
[46] Mizuno Y, Naoi T, Nishikawa M, Rattanakiat S, Hamaguchi N, Hashida M, et al. Simultaneous
delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. J Control Release 2010;141:252–9.
[47] Lin JM, Li B, Rimmer E, VanRoey M, Jooss K. Enhancement of the anti-tumor efficacy of a
GM-CSF – secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Exp Hematol 2008;36:319–28.
[48] Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, et al. Granulocyte-macrophage –
colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer
Interdiscip Int J Am Cancer Soc 2003;97:186–200.
[49] Zheng Y, Dou Y, Duan L, Cong C, Gao A, Lai Q, et al. Using chemo-drugs or irradiation to break
immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol 2015;294:54–9.
[50] Pfannenstiel LW, Lam SSK, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic
cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010;263:79–87.
[51] Zhu Y, Liu N, Xiong SD, Zheng YJ, Chu YW. CD4+ Foxp3 + regulatory T-cell impairment by
paclitaxel is independent of toll-like receptor 4. Scand J Immunol 2011;73:301–8.
[52] McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, et al. The effect of topoisomerase
I inhibitors on the efficacy of T-cell-based cancer immunotherapy. JNCI J Natl Cancer Inst
2018;110:777–86.
[53] Frey B, Stache C, Rubner Y, Werthm€oller N, Schulz K, Sieber R, et al. Combined treatment of
human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can
in vitro induce tumor cell death forms with immunogenic potential. J Immunotoxicol 2012;9:301–13.
[54] Ciofani G, Danti S, D’Alessandro D, Moscato S, Petrini M, Menciassi A. Barium titanate
nanoparticles: highly cytocompatible dispersions in glycol-chitosan and doxorubicin complexes for
cancer therapy. Nanoscale Res Lett 2010;5:1093.
[55] Chew SA, Moscato S, George S, Azimi B, Danti S. Liver cancer: current and future trends using bio-
materials. Cancers (Basel) 2019;11:2026.
[56] Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters.
Prog Polym Sci 2011;36:887–913.
[57] Begines Ruiz B, Ortiz Cerda TA, Perez Aranda M, Martinez G, de los Santos M, Arg€uelles Arias F,
et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects.
Nanomaterials 2020;10(7):1403–2020.
[58] Yong S-B, Chung JY, Kim SS, Choi HS, Kim Y-H. CD64-targeted HO-1 RNA interference
enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone
marrow cells. Biomaterials 2020;230:119651.
127Biomaterials and devices for immunotherapy
128 Emily M. Jordan et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[59] Lan X, She J, Lin D, Xu Y, Li X, Yang W, et al. Microneedle-mediated delivery of lipid-coated cis-
platin nanoparticles for efficient and safe cancer therapy. ACS Appl Mater Interfaces
2018;10:33060–9.
[60] Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov
2005;4:145–60.
[61] Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Drugs
1997;54:15–21.
[62] Barenholz YC. Doxil
®
—the first FDA-approved nano-drug: lessons learned. J Control Release
2012;160:117–34.
[63] Xu L, Liu Y, Chen Z, Li W, Liu Y, Wang L, et al. Surface-engineered gold nanorods: promising DNA
vaccine adjuvant for HIV-1 treatment. Nano Lett 2012;12:2003–12.
[64] Ungureanu C, Kroes R, Petersen W, Groothuis TAM, Ungureanu F, Janssen H, et al. Light inter-
actions with gold nanorods and cells: implications for photothermal nanotherapeutics. Nano Lett
2011;11:1887–94.
[65] Kuo W-S, Chang C-N, Chang Y-T, Yang M-H, Chien Y-H, Chen S-J, et al. Gold nanorods in
photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angew Chem
2010;122:2771–5.
[66] Wang J, Zhu G, You M, Song E, Shukoor MI, Zhang K, et al. Assembly of aptamer switch probes and
photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy. ACS
Nano 2012;6:5070–7.
[67] Zhang M, Xu R, Xia X, Yang Y, Gu J, Qin G, et al. Polycation-functionalized nanoporous silicon
particles for gene silencing on breast cancer cells. Biomaterials 2014;35:423–31.
[68] Barnes TJ, Jarvis KL, Prestidge CA. Recent advances in porous silicon technology for drug delivery.
Ther Deliv 2013;4:811–23.
[69] Santos HA, Bimbo LM, Herranz B, Shahbazi M-A, Hirvonen J, Salonen J. Nanostructured porous
silicon in preclinical imaging: moving from bench to bedside. J Mater Res 2013;28:152.
[70] Shahbazi M-A, Hamidi M, M€akil€a EM, Zhang H, Almeida PV, Kaasalainen M, et al. The mechanisms
of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013;34:7776–89.
[71] Shahbazi M-A, Almeida PV, M€akil€a E, Correia A, Ferreira MPA, Kaasalainen M, et al. Poly (methyl
vinyl ether-alt-maleic acid)-functionalized porous silicon nanoparticles for enhanced stability and cellular internalization. Macromol Rapid Commun 2014;35:624–9.
[72] Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, et al. Specific targeting
of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a
clinical 1.5-T magnetic resonance scanner. Cancer Res 2007;67:1555–62.
[73] Nelson BJ, Kaliakatsos IK, Abbott JJ. Microrobots for minimally invasive medicine. Annu Rev
Biomed Eng 2010;12:55–85.
[74] Li J, de A´vila BE-F, Gao W, Zhang L, Wang J. Micro/nanorobots for biomedicine: delivery, surgery,
sensing, and detoxification. Sci Robot 2017;2.
[75] Wang J. Nanomachines: fundamentals and applications. John Wiley & Sons; 2013.
[76] Wang W, Duan W, Ahmed S, Mallouk TE, Sen A. Small power: autonomous nano-and micromotors
propelled by self-generated gradients. Nano Today 2013;8:531–54.
[77] Sa´nchez S, Soler L, Katuri J. Chemically powered micro-and nanomotors. Angew Chem Int Ed
2015;54:1414–44.
[78] Chen X-Z, Jang B, Ahmed D, Hu C, De Marco C, Hoop M, et al. Small-scale machines driven by
external power sources. Adv Mater 2018;30:1705061.
[79] Chen C, Soto F, Karshalev E, Li J, Wang J. Hybrid nanovehicles: one machine, two engines. Adv
Funct Mater 2019;29:1806290.
[80] Vinagre BM, Tejado I, Traver JE. There’s plenty of fractional at the bottom, I: Brownian motors and
swimming microrobots. Fract Calc Appl Anal 2016;19:1282.
[81] Purcell EM. Life at low Reynolds number. Am J Phys 1977;45:3–11.
[82] Berg HC. The rotary motor of bacterial flagella. Annu Rev Biochem 2003;72:19
–54.
[83] Lauga E, Powers TR. The hydrodynamics of swimming microorganisms. Rep Prog Phys
2009;72:96601.
[84] Walker D, K€asdorf BT, Jeong H-H, Lieleg O, Fischer P. Enzymatically active biomimetic micro-
propellers for the penetration of mucin gels. Sci Adv 2015;1, e1500501.
[85] Luo M, Feng Y, Wang T, Guan J. Micro-/nanorobots at work in active drug delivery. Adv Funct
Mater 2018;28:1706100.
[86] Gao W, Wang J. Synthetic micro/nanomotors in drug delivery. Nanoscale 2014;6:10486–94.
[87] Erkoc P, Yasa IC, Ceylan H, Yasa O, Alapan Y, Sitti M. Mobile microrobots for active therapeutic
delivery. Adv Ther 2019;2:1800064.
[88] Wang S, Liu K, Wang F, Peng F, Tu Y. The application of micro-and nanomotors in classified drug
delivery. Chem Asian J 2019;14:2336–47.
[89] Sokolov IL, Cherkasov VR, Tregubov AA, Buiucli SR, Nikitin MP. Smart materials on the way to
theranostic nanorobots: molecular machines and nanomotors, advanced biosensors, and intelligent
vehicles for drug delivery. Biochim Biophys Acta 2017;1861:1530–44.
[90] Chen X-Z, Hoop M, Mushtaq F, Siringil E, Hu C, Nelson BJ, et al. Recent developments in mag-
netically driven micro-and nanorobots. Appl Mater Today 2017;9:37–48.
[91] Guo J, Gallegos JJ, Tom AR, Fan D. Electric-field-guided precision manipulation of catalytic
nanomotors for cargo delivery and powering nanoelectromechanical devices. ACS Nano
2018;12:1179–87.
[92] Wang J, Xiong Z, Zheng J, Zhan X, Tang J. Light-driven micro/nanomotor for promising biomed-
ical tools: principle, challenge, and prospect. Acc Chem Res 2018;51:1957–65.
[93] Lu X, Shen H, Zhao K, Wang Z, Peng H, Liu W. Micro-/nanomachines driven by ultrasonic power
sources. Chem Asian J 2019;14:2406–16.
[94] Saito K, Iwata K, Ishihara Y, Sugita K, Takato M, Uchikoba F. Miniaturized rotary actuators using
shape memory alloy for insect-type MEMS microrobot. Micromachines 2016;7:58.
[95] Soto F, Wang J, Ahmed R, Demirci U. Medical micro/nanorobots in precision medicine. Adv Sci
2020;7, 2002203.
[96] Alcanzare MM, Karttunen M, Ala-Nissila T. Propulsion and controlled steering of magnetic
nanohelices. Soft Matter 2019;15:1684–91.
[97] Pal M, Somalwar N, Singh A, Bhat R, Eswarappa SM, Saini DK, et al. Maneuverability of magnetic
nanomotors inside living cells. Adv Mater 2018;30:1800429.
[98] Qiu F, Mhanna R, Zhang L, Ding Y, Fujita S, Nelson BJ. Artificial bacterial flagella functionalized
with temperature-sensitive liposomes for controlled release. Sensors Actuators B Chem
2014;196:676–81.
[99] Ali J, Cheang UK, Martindale JD, Jabbarzadeh M, Fu HC, Kim MJ. Bacteria-inspired nanorobots
with flagellar polymorphic transformations and bundling. Sci Rep 2017;7:1–10.
[100] Zhang L, Abbott JJ, Dong L, Kratochvil BE, Bell D, Nelson BJ. Artificial bacterial flagella: fabrication
and magnetic control. Appl Phys Lett 2009;94:64107.
[101] Gao W, Sattayasamitsathit S, Manesh KM, Weihs D, Wang J. Magnetically powered flexible metal
nanowire motors. J Am Chem Soc 2010;132:14403–5.
[102] Jang B, Gutman E, Stucki N, Seitz BF, Wendel-Garc\’\ia PD, Newton T, et al. Undulatory loco-
motion of magnetic multilink nanoswimmers. Nano Lett 2015;15:4829–33.
[103] Tasci TO, Herson PS, Neeves KB, Marr DWM. Surface-enabled propulsion and control of colloidal
microwheels. Nat Commun 2016;7:1–6.
[104] Zhang L, Petit T, Lu Y, Kratochvil BE, Peyer KE, Pei R, et al. Controlled propulsion and cargo trans-
port of rotating nickel nanowires near a patterned solid surface. ACS Nano 2010;4:6228–34.
[105] Hu M, Ge X, Chen X, Mao W, Qian X, Yuan W-E. Micro/nanorobot: a promising targeted drug
delivery system. Pharmaceutics 2020;12:665.
[106] Dong R, Zhang Q, Gao W, Pei A, Ren B. Highly efficient light-driven TiO
– Au Janus micro-
2
motors. ACS Nano 2016;10:839–44.
[107] Villa K, Pumera M. Fuel-free light-driven micro/nanomachines: artificial active matter mimicking
nature. Chem Soc Rev 2019;48:4966–78.
[108] Wu Z, Si T, Gao W, Lin X, Wang J, He Q. Superfast near-infrared light-driven polymer multilayer
rockets. Small 2016;12:577–82.
[109] Li J, Li T, Xu T, Kiristi M, Liu W, Wu Z, et al. Magneto – acoustic hybrid nanomotor. Nano Lett
2015;15:4814–21.
129Biomaterials and devices for immunotherapy
130 Emily M. Jordan et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[110] Garcia-Gradilla V, Orozco J, Sattayasamitsathit S, Soto F, Kuralay F, Pourazary A, et al.
Functionalized ultrasound-propelled magnetically guided nanomotors: Toward practical biomedical
applications. ACS Nano 2013;7:9232–40.
[111] Basta G, Venneri L, Lazzerini G, Pasanisi E, Pianelli M, Vesentini N, et al. In vitro modulation of
intracellular oxidative stress of endothelial cells by diagnostic cardiac ultrasound. Cardiovasc Res
2003;58:156–61.
[112] Medina-Sa´nchez M, Xu H, Schmidt OG. Micro-and nano-motors: the new generation of drug car-
riers. Ther Deliv 2018;9:303–16.
[113] Mou F, Chen C, Ma H, Yin Y, Wu Q, Guan J. Self-propelled micromotors driven by the
magnesium – water reaction and their hemolytic properties. Angew Chem Int Ed 2013;52:7208–12.
[114] Patin˜o T, Arque X, Mestre R, Palacios L, Sa´nchez S. Fundamental aspects of enzyme-powered micro-
and nanoswimmers. Acc Chem Res 2018;51:2662–71.
[115] Tu Y, Peng F, White PB, Wilson DA. Redox-sensitive stomatocyte nanomotors: destruction and
drug release in the presence of glutathione. Angew Chem Int Ed 2017;56:7620–4.
[116] Llopis-Lorente A, Garcı`a-Ferna´ndez A, Lucena-Sa´nchez E, Dı`ez P, Sanceno´n F, Villalonga R, et al.
Stimulus-responsive nanomotors based on gated enzyme-powered Janus Au – mesoporous silica
nanoparticles for enhanced cargo delivery. Chem Commun 2019;55:13164–7.
[117] Min J, Yang Y, Wu Z, Gao W. Robotics in the gut. Adv Ther 2020;3:1900125.
[118] Gao W, Kagan D, Pak OS, Clawson C, Campuzano S, Chuluun-Erdene E, et al. Cargo-towing fuel-
free magnetic nanoswimmers for targeted drug delivery. Small 2012;8:460–7.
[119] Mhanna R, Qiu F, Zhang L, Ding Y, Sugihara K, Zenobi-Wong M, et al. Artificial bacterial flagella
for remote-controlled targeted single-cell drug delivery. Small 2014;10:1953–7.
[120] Qiu F, Fujita S, Mhanna R, Zhang L, Simona BR, Nelson BJ. Magnetic helical microswimmers
functionalized with lipoplexes for targeted gene delivery. Adv Funct Mater 2015;25:1666–71.
[121] Gutman E, Or Y. Optimizing an undulating magnetic microswimmer for cargo towing. Phys Rev
E 2016;93:63105.
[122] Liu M, Pan L, Piao H, Sun H, Huang X, Peng C, et al. Magnetically actuated wormlike nanomotors
for controlled cargo release. ACS Appl Mater Interfaces 2015;7:26017–21.
[123] Sun M, Fan X, Meng X, Song J, Chen W, Sun L, et al. Magnetic biohybrid micromotors with high
maneuverability for efficient drug loading and targeted drug delivery. Nanoscale 2019;11:18382–92.
[124] Villa K, Krejcova´L, Novotny F, Heger Z, Sofer Z, Pumera M. Cooperative multifunctional self-
propelled paramagnetic microrobots with chemical handles for cell manipulation and drug delivery.
Adv Funct Mater 2018;28:1804343.
[125] Andhari SS, Wavhale RD, Dhobale KD, Tawade BV, Chate GP, Patil YN, et al. Self-propelling
targeted magneto-nanobots for deep tumor penetration and pH-responsive intracellular drug delivery.
Sci Rep 2020;10:1–16.
[126]
Bozuyuk U, Yasa O, Yasa IC, Ceylan H, Kizilel S, Sitti M. Light-triggered drug release from
3D-printed magnetic chitosan microswimmers. ACS Nano 2018;12:9617–25.
[127] Alapan Y, Bozuyuk U, Erkoc P, Karacakol AC, Sitti M. Multifunctional surface microrollers for
targeted cargo delivery in physiological blood flow. Sci Robot 2020;5, eaba5726.
[128] Wang X, Qin X-H, Hu C, Terzopoulou A, Chen X-Z, Huang T-Y, et al. 3D printed enzymatically
biodegradable soft helical microswimmers. Adv Funct Mater 2018;28:1804107.
[129] Wang X, Chen X-Z, Alc^antara CCJ, Sevim S, Hoop M, Terzopoulou A, et al. MOF-based micro-
robots: MOFBOTS: metal-organic-framework-based biomedical microrobots. Adv Mater
2019;31:1970192.
[130] Kaminski MD, Xie Y, Mertz CJ, Finck MR, Chen H, Rosengart AJ. Encapsulation and release of
plasminogen activator from biodegradable magnetic microcarriers. Eur J Pharm Sci 2008;35:96–103.
[131] Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, et al. Shear-activated
nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012;337:738 –42.
[132] Cheng R, Huang W, Huang L, Yang B, Mao L, Jin K, et al. Acceleration of tissue plasminogen
activator-mediated thrombolysis by magnetically powered nanomotors. ACS Nano 2014;8:7746–54.
[133] Hu J, Huang W, Huang S, ZhuGe Q, Jin K, Zhao Y. Magnetically active Fe
nanorods loaded with
3O4
tissue plasminogen activator for enhanced thrombolysis. Nano Res 2016;9:2652–61.
[134] Hu J, Huang S, Zhu L, Huang W, Zhao Y, Jin K, et al. Tissue plasminogen activator-porous magnetic
microrods for targeted thrombolytic therapy after ischemic stroke. ACS Appl Mater Interfaces
2018;10:32988–97.
[135] Rahman MM, Chowdhury MM, Alam MK. Rotating-electric-field-induced carbon-nanotube-
based nanomotor in water: a molecular dynamics study. Small 2017;13:1603978.
[136] Xu X, Kim K, Fan D. Tunable release of multiplex biochemicals by plasmonically active rotary
nanomotors. Angew Chem 2015;127:2555–9.
[137] Kim K, Guo J, Xu X, Fan D. Micromotors with step-motor characteristics by controlled magnetic
interactions among assembled components. ACS Nano 2015;9:548–54.
[138] Fan D, Yin Z, Cheong R, Zhu FQ, Cammarata RC, Chien CL, et al. Subcellular-resolution delivery
of a cytokine through precisely manipulated nanowires. Nat Nanotechnol 2010;5:545–51.
[139] Zhan X, Zheng J, Zhao Y, Zhu B, Cheng R, Wang J, et al. From strong dichroic nanomotor to pol-
arotactic microswimmer. Adv Mater 2019;31:1903329.
[140] Wang Q, Dong R, Wang C, Xu S, Chen D, Liang Y, et al. Glucose-fueled micromotors with highly
efficient visible-light photocatalytic propulsion. ACS Appl Mater Interfaces 2019;11:6201–7.
[141] Xuan M, Shao J, Gao C, Wang W, Dai L, He Q. Self-propelled nanomotors for thermomechanically
percolating cell membranes. Angew Chem Int Ed 2018;57:12463–7.
[142] Garcia-Gradilla V, Sattayasamitsathit S, Soto F, Kuralay F, Yardı`mcı`C, Wiitala D, et al. Ultrasound-
propelled nanoporous gold wire for efficient drug loading and release. Small 2014;10:4154–9.
[143] Hoop M, Mushtaq F, Hurter C, Chen X-Z, Nelson BJ, Pane S. A smart multifunctional drug delivery
nanoplatform for targeting cancer cells. Nanoscale 2016;8:12723–8.
[144] Fusco S, Huang H-W, Peyer KE, Peters C, H€aberli M, Ulbers A, et al. Shape-switching microrobots
for medical applications: the influence of shape in drug delivery and locomotion. ACS Appl Mater
Interfaces 2015;7:6803–11.
[145] Fusco S, Chatzipirpiridis G, Sivaraman KM, Ergeneman O, Nelson BJ, Pane S. Chitosan electrode-
position for microrobotic drug delivery. Adv Healthc Mater 2013;2:1037–44.
[146] Dı`ez P, de Avila BE-F, Ramı`rez-Herrera DE, Villalonga R, Wang J. Biomedical nanomotors: effi-
cient glucose-mediated insulin release. Nanoscale 2017;9:14307–11.
[147] Khezri B, Beladi Mousavi SM, Krejcova´L, Heger Z, Sofer Z, Pumera M. Ultrafast electrochemical
trigger drug delivery mechanism for nanographene micromachines. Adv Funct Mater
2019;29:1806696.
[148] Hortela˜o AC, Patin˜o T, Perez-Jimenez A, Blanco A`,Sa´nchez S. Enzyme-powered nanobots enhance
anticancer drug delivery. Adv Funct Mater 2018;28:1705086.
[149] Liu K, Ou J, Wang S, Gao J, Liu L, Ye Y, et al. Magnesium-based micromotors for enhanced active
and synergistic hydrogen chemotherapy. Appl Mater Today 2020;20:100694.
[150]
Zhou M, Hou T, Li J, Yu S, Xu Z, Yin M, et al. Self-propelled and targeted drug delivery of poly
(aspartic acid)/iron – zinc microrocket in the stomach. ACS Nano 2019;13:1324–32.
[151] Wu Z, Lin X, Zou X, Sun J, He Q. Biodegradable protein-based rockets for drug transportation and
light-triggered release. ACS Appl Mater Interfaces 2015;7:250–5.
[152] Mou F, Chen C, Zhong Q, Yin Y, Ma H, Guan J. Autonomous motion and temperature-controlled
drug delivery of Mg/Pt-poly (N-isopropylacrylamide) Janus micromotors driven by simulated body
fluid and blood plasma. ACS Appl Mater Interfaces 2014;6:9897–903.
[153] Li J, Angsantikul P, Liu W, de A´vila B, Thamphiwatana S, Xu M, et al. Micromotors spontaneously
neutralize gastric acid for pH-responsive payload release. Angew Chem Int Ed 2017;56:2156–61.
[154] de A´vila BE-F, Angsantikul P, Li J, Lopez-Ramirez MA, Ramirez-Herrera DE, Thamphiwatana S,
et al. Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. Nat
Commun 2017;8:1–9.
[155] Paryab A, Hosseini HRM, Abedini F, Dabbagh A. Synthesis of magnesium-based Janus micromotors
capable of magnetic navigation and antibiotic drug incorporation. New J Chem 2020;44:6947–57.
[156] Tu Y, Peng F, Andre AAM, Men Y, Srinivas M, Wilson DA. Biodegradable hybrid stomatocyte
nanomotors for drug delivery. ACS Nano 2017;11:1957–63.
[157] Wu Y, Lin X, Wu Z, M€ohwald H, He Q. Self-propelled polymer multilayer Janus capsules for effec-
tive drug delivery and light-triggered release. ACS Appl Mater Interfaces 2014;6:10476–81.
131Biomaterials and devices for immunotherapy
132 Emily M. Jordan et al.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
[158] Baylis JR, John AES, Wang X, Lim EB, Statz ML, Chien D, et al. Self-propelled dressings containing
thrombin and tranexamic acid improve short-term survival in a swine model of lethal junctional hem-
orrhage. Shock 2016;46:123.
[159] Baylis JR, Yeon JH, Thomson MH, Kazerooni A, Wang X, John AES, et al. Self-propelled particles
that transport cargo through flowing blood and halt hemorrhage. Sci Adv 2015;1, e1500379.
[160] Wei X, Beltra´n-Gastelum M, Karshalev E, de A´vila B, Zhou J, Ran D, et al. Biomimetic micromotor
enables active delivery of antigens for oral vaccination. Nano Lett 2019;19:1914–21.
[161] Lopez-Ramirez MA, Soto F, Wang C, Rueda R, Shukla S, Silva-Lopez C, et al. Built-in active
microneedle patch with enhanced autonomous drug delivery. Adv Mater 2020;32:1905740.
[162] Li H, Wen T, Wang T, Ji Y, Shen Y, Chen J, et al. In vivo metabolic response upon exposure to gold
nanorod core/silver shell nanostructures: modulation of inflammation and upregulation of dopamine.
Int J Mol Sci 2020;21:384.
[163] Lu Y, Chen W, Ke W, Wu S. Nickel-based (Ni-Cr and Ni-Cr-Be) alloys used in dental restorations
may be a potential cause for immune-mediated hypersensitivity. Med Hypotheses 2009;73:716–7.
[164] Ceylan H, Yasa IC, Yasa O, Tabak AF, Giltinan J, Sitti M. 3D-printed biodegradable microswimmer
for theranostic cargo delivery and release. ACS Nano 2019;13:3353–62.
[165] Azimi B, Milazzo M, Lazzeri A, Berrettini S, Uddin MJ, Qin Z, et al. Electrospinning piezoelectric
fibers for biocompatible devices. Adv Healthc Mater 2019;9:e1901287. https://doi.org/10.1002/
adhm.201901287.
[166] Kapat K, Shubhra QTH, Zhou M, Leeuwenburgh S. Piezoelectric nano-biomaterials for biomedicine
and tissue regeneration. Adv Funct Mater 2020;30, 1909045.
[167] Mushtaq F, Torlakcik H, Hoop M, Jang B, Carlson F, Grunow T, et al. Motile piezoelectric nanoeels
for targeted drug delivery. Adv Funct Mater 2019;29:1808135.
[168] Chen X-Z, Hoop M, Shamsudhin N, Huang T,€Ozkale B, Li Q, et al. Hybrid magnetoelectric nano-
wires for nanorobotic applications: fabrication, magnetoelectric coupling, and magnetically assisted
in vitro targeted drug delivery. Adv Mater 2017;29:1605458.
[169] Duan X, Chan C, Han W, Guo N, Weichselbaum RR, Lin W. Immunostimulatory nanomedicines
synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat Commun
2019;10:1–15.
[170] Gao F, Zhang C, Qiu W-X, Dong X, Zheng D-W, Wu W, et al. PD-1 blockade for improving the
antitumor efficiency of polymer-doxorubicin nanoprodrug. Small 2018;14:1802403.
[171] He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, et al. Core-shell nanoscale coordi-
nation polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint block-
ade cancer immunotherapy. Nat Commun 2016;7:1–12.
[172] Kuai R, Yuan W, Son S, Nam J, Xu Y, Fan Y, et al. Elimination of established tumors with nanodisc-
based combination chemoimmunotherapy. Sci Adv 2018;4, eaao1736.
[173] Ringgaard L, Melander F, Eliasen R, Henriksen JR, Jølck RI, Engel TB, et al. Tumor repolarization
by an advanced liposomal drug delivery system provides a potent new approach for chemo-
immunotherapy. Sci Adv 2020;6, eaba5628.
[174] Kedar E, Klein E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv
Cancer Res 1992;59:245–322.
[175] Kedar E, Braun E, Rutkowski Y, Emanuel N, Barenholz Y. Delivery of cytokines by liposomes. II.
Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and
anti-tumor activity in mice. J Immunother 1994;16:115–24.
[176] Refaat D, Aggour MG, Farghali AA, Mahajan R, Wiklander JG, Nicholls IA, et al. Strategies for
molecular imprinting and the evolution of MIP nanoparticles as plastic antibodies—synthesis and
applications. Int J Mol Sci 2019;20:6304.
[177] Zhang H. Molecularly imprinted nanoparticles for biomedical applications. Adv Mater
2020;32:1806328.
[178] Yasa IC, Ceylan H, Bozuyuk U, Wild A-M, Sitti M. Elucidating the interaction dynamics between
microswimmer body and immune system for medical microrobots. Sci Robot 2020;5, eaaz3867.
[179] Li C, Guo C, Fitzpatrick V, Ibrahim A, Zwierstra MJ, Hanna P, et al. Design of biodegradable,
implantable devices towards clinical translation. Nat Rev Mater 2020;5:61–81.
[180] Yan X, Zhou Q, Vincent M, Deng Y, Yu J, Xu J, et al. Multifunctional biohybrid magnetite micro-
robots for imaging-guided therapy. Sci Robot 2017;2, eaaq1155.
[181] Karshalev E, de A´vila B, Beltra´n-Gastelum M, Angsantikul P, Tang S, Mundaca-Uribe R, et al.
Micromotor pills as a dynamic oral delivery platform. ACS Nano 2018;12:8397–405.
[182] Ricci C, Moroni L, Danti S. Cancer tissue engineering-new perspectives in understanding the biology
of solid tumours-a critical review. OA Tissue Eng 2013;1:1–4.
[183] Ceylan H, Yasa IC, Kilic U, Hu W, Sitti M. Translational prospects of untethered medical micro-
robots. Prog Biomed Eng 2019;1:12002.
133Biomaterials and devices for immunotherapy
CHAPTER FIVE
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Engineered devices for tumor
microenvironment immune modulation
Alexander M. Cryer
a
Department of Medicine, Division of Engineering in Medicine, Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA, United States
b
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, United States
a,b
and Natalie Artzi
a,b
Contents
1. Introduction 135
2. Local delivery of engineered devices for tumor immune modulation 136
3. Transdermal delivery of engineered devices for tumor immune modulation 145
4. Systemic delivery of engineered devices for tumor immune modulation 149
5. Limitations, perspectives and future work 151
References 152
1. Introduction
As our understanding of how the interaction between the immune system and the
tumor dictates the progression of the disease has increased, so have the opportunities to
intervene therapeutically. The advent of immunoengineering describes the marriage of
immunology and bioengineering to create and understand complex systems for the remediation of tumors. Utilization of an engineer’s toolkit can lead to the construction of
devices designed to operate in an immunological space, that is, to provide a modulatory
effect within the often immunologically quiescent tumor microenvironment (TME).
Engineered devices include particle-based systems (nanoparticles, NPs), hydrogels, scaffolds, stents, microneedle patches, and electronic microchips. As tumors subvert destruction by the immune system in a multiplicity of ways, engineered devices principally act to
reawaken and reprogram the antitumor arm of the immune system. The advantages of
these devices are that immunotherapies can be delivered with spatiotemporal control and
preferential localization, as well as multitherapy combinations, utilizing several routes of
administration. Indeed, leveraging our understanding of tumor immunology in the
design of these devices can lead to improved pharmacokinetics (PK) and biodistribution
(BD) of therapies and therefore efficacy. This, in turn, increases residence time at the
Engineering Technologies and Clinical Translation Copyright © 2022 Elsevier Inc.
All rights reserved.https://doi.org/10.1016/B978-0-323-90949-5.00005-X
135
Соседние файлы в папке Библиотека им академика М.И. Перельмана